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Abstract
Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening
toxicities can occur from irinotecan treatment. Although multiple genes may play a role in
irinotecan activity, the majority of evidence to date suggests that variation in expression of
UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is strongly associated with
toxicity; however, this link is dose dependent. Variations in other pharmacokinetic genes,
particularly the transporter ABCC2, also contribute to irinotecan toxicity. In addition, recent
studies have shown that pharmacodynamic genes such as TDP1 and XRCC1 can also play a role in
both toxicity and response.
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Camptothecin, a cytotoxic agent found in Camptotheca acuminata, was developed as an
anticancer agent in the early 1970s [1–3]. Its mechanism of action is to bind to the DNA/
topoisomerase I complex during DNA replication, preventing the resealing of single-strand
breaks. Ultimately, the replication machinery collides with the camptothecin/toposiomerase
I complex, shattering the DNA [4]. However, camptothecin is insoluble and attempts to
address this both reduced the efficacy and increased the toxicity of the drug.
Camptothecin analogs were developed in the 1990s to circumvent the solubility problems.
Irinotecan (also known as CPT-11, Camptosar®) is an analog approved for first-line therapy
of advanced colorectal cancer in combination with 5-fluorouracil and/or leucovorin. In
addition, irinotecan/cisplatin combination therapy is used for other cancers, for example
lung and ovarian [5–6]. Recent studies have involved the combination of irinotecan with
bevacizumab or cetuximab [1–2,7–8].
Diarrhea and neutropenia are major limiting factors for irinotecan, with up to 36% of
patients experiencing severe, potentially life-threatening toxicities [9]. Methods such as
pharmacogenomics to prospectively screen patients for DNA variations (Table 1) prior to
selecting irinotecan therapy or dose would help improve patient care and reduce healthcare
costs [10–12].
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Irinotecan is a prodrug, metabolized into the active form, SN-38, via human
carboxylesterases CES1 and CES2. CYP3A4 converts irinotecan into the inactive
metabolite, APC. The active SN-38 can be subsequently inactivated through glucuronidation
via members of the UDP-glucuronosyltransferase family [12]. UGT1A enzymes are a
product of alternative splicing from the UGT1A locus located on chromosome 2q37. A total
of 13 UGT1A genes are encoded at this locus (including four pseudogenes). Each UGT1A
enzyme has a unique promoter and a unique exon 1, while the remaining four exons are
shared with all members of the UGT1A family [13].
Metabolism pharmacogenomics
Carboxylesterases—Carboxylesterase 2 is the key enzyme responsible for hydrolyzing
CPT-11 to the active SN-38 form [14]. CES2 expression is highly variable among
individuals [15–16], and in vitro studies suggest that increased CES2 expression leads to
increased irinotecan metabolism [17]. However, extensive assessment of the CES2 gene did
not identify any functional polymorphisms [18–19], and characterization of a common
promoter variant in the 5′-UTR of CES2 (referred to as 830C>G; located at −171C>G) did
not identify any associations with CES2 expression or catalytic activity, or irinotecan
toxicity or outcome [20]. CES2 is, however, controlled by three distinct promoter regions
[21], and it is possible that control of promoter choice may explain some of the individual
variation in CES2 expression.
CES1 plays a minor role in irinotecan metabolism, and extensive resequencing of CES1 also
did not identify any functional polymorphisms [18]. However, in a Japanese hypertensive
patient population, a −816A>C variant in the CES1 promoter region has been reported to
affect CES1 promoter activity [22], but this remains to be assessed in the context of
irinotecan metabolism.
CYP3A4—CYP3A4 inactivates irinotecan through conversion into the metabolite APC
[23]. While there is no evidence of variants in the CYP3A4 gene providing a useful screen
for APC conversion, the interindividual variability in CYP3A4 activity can be exploited for
irinotecan dosing [24].
UGT1A1—The most comprehensively studied genetic marker linked to toxicity from
irinotecan therapy is found in the UDP-glucuronosyltransferase gene, UGT1A1. The
UGT1A1 enzyme is responsible for hepatic bilirubin glucuronidation, and reduced UGT1A1
expression leads to Gilbert's syndrome [25]. Expression of UGT1A1 is, in part, controlled
by a polymorphic dinucleotide repeat within the UGT1A1 promoter TATA element
consisting of between five and eight copies of a TA repeat ([TA]nTAA), with the (TA)6TAA
allele the most common (considered wild-type) and (TA)7TAA the most frequently recorded
variant allele (usually denoted UGT1A1*28) [26]. The longer the repeat allele, the lower the
corresponding UGT1A1 gene expression, with patients carrying the (TA)7TAA and
(TA)8TAA alleles having significantly lower UGT1A1 expression. The frequency of the
UGT1A1*28 allele has been assessed worldwide and ranges from approximately 15% in
Asians to 45% in Africans. It is also found in 26–38% of Caucasians, African–Americans
and Hispanics [27–29]. As increasing the number of TA repeats decreases UGT1A1
expression, the presence of more than six TA repeats in the UGT1A1 promoter region leads
to reduced glucuronidation, including reduced SN-38G formation. This results in an excess
build-up of SN-38, leading to toxicity [12,25,30].
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Early studies confirmed the link between UGT1A1*28 and irinotecan toxicity, specifically
diarrhea and neutropenia [27,31], and a retrospective analysis of DNA from 524 metastatic
colorectal cancer patients on the N9741 study also associated UGT1A1*28 with the
incidence of toxicities (neutropenia, febrile neutropenia and vomiting) [32]. Furthermore, a
prospective study of 66 patients with advanced disease treated with irinotecan found that
patients homozygous for UGT1A1*28 had a significantly greater risk of grade IV
neutropenia compared with patients with at least one wild-type allele [33].
UGT1A1 in the clinic—In 2005, the US FDA approved a genetic test for UGT1A1*28
[34] and altered the irinotecan package insert to include toxicity and dosing warnings
relating to the UGT1A1*28 allele [35]. This marked a significant step towards incorporating
pharmacogenomics into clinical practice. However, 5 years on, concerns still remain over
the specific irinotecan dose required based on genotype [36–37]. A subsequent study has
identified that the relationship between UGT1A1*28 and irinotecan toxicity is dependent on
the irinotecan regimen used, rendering UGT1A1*28 unsuitable as a marker for toxicity with
lower doses (50–180 mg/m2). For moderate-to-high doses (200–350 mg/m2), the risk of
severe hematological toxicity in patients homozygous for UGT1A1*28 is 27.8-times higher
than for patients with at least one wild-type allele [38]. Furthermore, a European study
confirmed that toxicity from low-dose irinotecan was not affected by the UGT1A1*28
variant [39]. Consequently, it appears necessary to further amend the irinotecan package
insert to include dose/genotype guidelines. A recent prospective European study of 59
patients showed that when UGT1A1*28 homozygous patients are excluded; the standard 180
mg/m2 dose is significantly lower than the irinotecan dose that can be tolerated [40]. Dosing
information from a Japanese Phase I study of 27 patients receiving irinotecan and
doxifluridine has suggested a starting dose of 70 mg/m2 for patients heterozygous for
UGT1A1*28. No homozygous patients were identified in this study [41].
Other UGT1A1 polymorphisms—There are other significant polymorphisms in the
UGT1A1 gene. Patients with haplotypes containing both the −3156G>A variant and
UGT1A1*28 experienced significantly higher incidence of severe neutropenia compared
with patients with haplotypes not containing −3156G>A [33], and in the N9741 study the
UGT1A1 −3156 variant was associated with a significantly increased risk of neutropenia
[32]. In Caucasian populations, the *28 and −3156 alleles are in strong linkage
disequilibrium [33].
In Asian populations where the frequency of UGT1A1*28 is low [42], other UGT1A1
variants can also play a role in irinotecan toxicity [12,43–50]. For example, in Korean
patients with non-small-cell lung cancer treated with irinotecan-containing therapy, there
were associations between the exon 1 polymorphism UGT1A1*6 (G71R), irinotecan
pharmacokinetics, and toxicity from irinotecan therapy [47]. In a further study of 88
Japanese cancer patients receiving irinotecan, two haplotype groups were associated with
reduced area under the curve (AUC) ratios of SN-38G to SN-38, which is predicted to have
an effect on irinotecan toxicity. These haplotypes were denoted *28 (containing the
UGT1A1*28 allele) and *6 (containing the exon 1 G71R polymorphism) [44]. Patients with
the *6 haplotype alone did not show significant variation in their AUC ratios; however,
patients with one *6 haplotype and one *28 haplotype had significantly lower AUC ratios
compared with patients with homozygous wild-type UGT1A1 [44].
Other UGT1A genes—Variants in UGT1A7 and UGT1A9 are also associated with SN-38
glucuronidation [51] and irinotecan toxicities (particularly diarrhea) [47,52,53], although
these studies require further exploration. UGT1A7*3 has been associated with hematologic
toxicity in metastatic colorectal cancer patients treated with irinotecan [54]. Furthermore,
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UGT1A7*2 and *3, as well as UGT1A9 -118(dT) alleles, were associated with response to
irinotecan [52].
Transport
Irinotecan and SN-38 may be transported out of the cell via members of the ATP-binding
cassette transporter family [55], specifically ABCB1 (MDR1; P-glycoprotein), ABCC2
(CMOAT; MRP2) and ABCG2 (BCRP). In addition, glucuronidated SN-38 can be removed
from the cell by ABCC2 (Figure 1).
Transport pharmacogenomics
ABCB1—In 65 patients treated with irinotecan, the common ABCB1 1236C>T variant
caused significantly decreased clearance of irinotecan [56]. ABCB1 3435C>T was associated
with diarrhea caused by irinotecan-containing therapy in a subset of 87 patients from a
Phase III small-cell lung cancer trial [57]. In a further study, a haplotype containing the three
most commonly studied ABCB1 polymorphisms (1236C>T, 2677G>T and 3435C>T) was
associated with reduced renal clearance in 49 Asian patients receiving irinotecan [58]. The
ABCB1 haplotype was also associated with response and survival in 140 colorectal cancer
patients from the Nordic VI trial [59]. In the same study, ABCB1 3435C>T was also
predictive of early toxic events [59].
ABCC2—In 64 patients with solid tumors treated with irinotecan, a significant correlation
was observed with irinotecan and metabolite clearance, and the 3972T>C polymorphism
[43], which was also associated with toxicity [60]. ABCC2 -24T homozygotes and 3972T
homozygotes also experienced significantly better response rates and progression-free
survival in non-small-cell lung cancer patients receiving irinotecan and cisplatin [61]. In
addition, a haplotype in the multidrug transporter ABCC2 is associated with toxicity in
patients lacking UGT1A1*28 [46,62–63], suggesting that this haplotype could be a
secondary screen for patients who are wild-type for UGT1A1, to further reduce the risk of
toxicity.
ABCG2—Cell lines overexpressing ABCG2 are resistant to several topoisomerase I
inhibitors, including irinotecan [64] and SN-38 [65]. The ABCG2 variant 421C>A (Q141K)
reduced ABCG2 gene expression and caused irinotecan resistance in cancer cell lines [66]
and neutropenia in 55 patients receiving irinotecan monotherapy when assessed as a
haplotype with ABCG2 IVS12 +49G>T [67]. Alone, the ABCG2 421C>A variant was not
associated with toxicity [49,61]. A further polymorphism, ABCG2 34G>A, was significantly
associated with diarrhea in 107 cancer patients [60] but was not associated with toxicity or
outcome in 107 non-small-cell lung cancer patients [61].
Irinotecan pharmacodynamics
Topoisomerase I is the target for SN-38, and several downstream genes have been
associated with camptothecin sensitivity, and are consequently included in the irinotecan
pathway (Figure 1) including XRCC1 [68], ADPRT [69], TDP1 [70], CDC45L [71] and NF-
κB1 [72–73].
Pharmacodynamics & pharmacogenomics
A retrospective analysis of 107 colorectal cancer patients identified a significant association
with TDP1 IVS12 +79T>G and grade 3/4 neutropenia, and the TDP1 variant and an XRCC1
haplotype and response to irinotecan [74]. Associations with toxicity were not seen in a
follow-up study of 85 cancer patients [75], although the dose of irinotecan was higher (300–
350 mg/m2 compared with a median of 180 mg/m2 in [74]), and no significant association
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with XRCC1 R399Q and toxicity was seen in 18 colorectal cancer patients [76]. However,
the variant XRCC1 R399Q was associated with overall survival in 43 Turkish metastatic
colorectal cancer patients [77]. Assessment of irinotecan pharmacodynamics in the context
of pharmacogenomics is in its infancy, and subsequent validation experiments are required.
Future perspective
Toxicity is a major dose-limiting, life-threatening side effect from irinotecan chemotherapy.
There are comprehensive data to suggest that UGT1A1*28 may provide a genetic marker
that patients can be screened for prior to irinotecan therapy and/or dose selection, and this
has the potential to be a cost-effective screening approach [78]. However, a decade on from
the initial association with toxicity, there are still questions remaining about how to interpret
the genetic information [37]. Moreover, UGT1A1*28 does not account for all the toxicity
seen from irinotecan therapy. Consequently, although screening for this allele can identify
patients at risk, the lack of UGT1A1*28 does not preclude the chances of a patient
experiencing severe toxicity.
Alongside variants in other UGT1A genes, transporters, and pharmacodynamic genes (Table
1), in vitro studies have shown that altered expression of PXR (encoded by the NR1I2 gene)
can affect SN-38 glucuronidation [79]. Consequently, variation in the NR1I2 gene should be
explored in the context of irinotecan therapy. Recent work has also suggested that epigenetic
factors, such as methylation, may also play a role in altering UGT1A1 expression [80], and
it is possible that screening of the tumor cells as well as germline DNA may also be needed
for a comprehensive irinotecan pharmacogenomic profile.
Conclusion
Although UGT1A1*28 provides a compelling story for irinotecan toxicity, it is not the only
answer. Variation in any gene involved in the irinotecan pathway (Figure 1) could play a
role in either toxicity or response. As well as polymorphisms, either assessed singly or in the
form of a haplotype, other genomic alterations, such as epigenetics, also need to be assessed
to build a comprehensive pharmacogenomic profile. This may require assessing DNA from
tumor tissue to analyze specific alterations in the tumor genome, alongside the more typical
germline DNA screening. Currently, markers for irinotecan response are few, and many
remain unvalidated. Further analysis, particularly of the pharmacodynamic genes, will
hopefully identify the genetic basis of response to irinotecan.
Executive summary
■ Irinotecan is approved, in combination, for the treatment of metastatic
colorectal cancer. It is also used for treating other solid tumors such as ovarian
and non-small-cell lung cancer.
■ Severe toxicity from irinotecan occurs in up to 36% of patients.
Irinotecan pharmacokinetics
■ A polymorphic dinucleotide repeat in the UGT1A1 promoter region
(UGT1A1*28) is significantly associated with irinotecan toxicity.
■ There is now a US FDA-approved test for UGT1A1*28, and the irinotecan
package insert contains warnings about UGT1A1*28 and risk of toxicity.
■ The UGT1A1*28 association with irinotecan toxicity is dose dependent.
■ Other UGT1A polymorphisms may also play a role in irinotecan toxicity,
especially in populations with a low incidence of UGT1A1*28.
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■ ABCB1 polymorphisms have been associated with both toxicity and response.
■ An ABCC2 haplotype may predict irinotecan toxicity in patients who are not
carriers of UGT1A1*28.
Irinotecan pharmacodynamics
■ Initial studies have shown that XRCC1 and TDP1 are associated with toxicity
and response.
Future perspective
■ Phase I studies aimed at determining UGT1A1*28-dependent dosing of
irinotecan will help to improve the use of irinotecan pharmacogenomics in
clinical practice.
■ Other pharmacogenomic studies, including expression panels and epigenetic
markers, may prove to be useful indicators of outcome and toxicity to
irinotecan.
Conclusion
■ Although UGT1A1*28 is a strong candidate as a pharmacogenomic marker for
irinotecan toxicity, a panel of markers will be required in order to be as
predictive as possible prior to irinotecan therapy selection or irinotecan dose
selection.
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Figure 1. Irinotecan cancer cell pathway
Reproduced with kind permission from PharmGKB and Stanford University [81].
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Table 1
Summary of genes and variants from irinotecan pharmacogenomics studies.
Gene Variant dbSNP ID Effect Ref.
ABCB1 1236C>T rs1128503 Decreased irinotecan clearance;
risk of toxicity and reduced
survival when in haplotype with
2677 and 3435
[56,58,59]
ABCB1 2677G>A/T rs2032582 Risk of toxicity and reduced
survival when in haplotype with
1236 and 3435
[58,59]
ABCB1 3435C>T rs1045642 Increased toxicity; risk of
toxicity and reduced survival
when in haplotype with 1236
and 2677
[57–59]
ABCC2 −24C>T rs717620 Increased response and survival
with 3972; toxicity as part of
ABCC2 haplotype in patients
without GT1A1*28
[46,61–63]
ABCC2 3972T>C rs3740066 Increased response and survival
with −24; toxicity as part of
ABCC2 haplotype in patients
without UGT1A1*28
[43,46,60–63]
ABCG2 34G>A rs2231137 Increased toxicity; no
association with toxicity and
outcome
[60,61]
ABCG2 421C>A; Q141K rs2231142 Reduced expression; irinotecan
resistance; toxicity with IVS12
+49G>T
[49,61,66,67]
ABCG2 IVS12+49G>T rs3832043 Toxicity with 421C>A [49,61,66,67]
CES1 −816A>C Unknown Altered CES1 promoter activity [22]
CES2 830C>G; −171C>G rs11075646 No association with expression,
catalytic activity, toxicity or
outcome
[20]
CYP3A4 Activity Altered irinotecan dosing
requirement
[24]
NR1I2 Expression Altered SN-38 glucuronidation [79]
TDP1 IVS12+79T>G rs2401863 Response; no toxicity
association at higher doses
[74,75]
UGT1A1 −3156G>A rs10929302 Increased risk of toxicity [32,33]
UGT1A1 (TA)7 TAA, *28 rs8175347 Increased risk of toxicity; dose
dependent
[32,33,38–41]
UGT1A1 G71R, *6 rs4148323 Increased risk of toxicity [44,47]
UGT1A7 *2 (N129K and R131K) rs17868323, rs17868324 SN-38 glucuronidation; response [47,52]
UGT1A7 *3 (N129K, R131K and W208R) rs17868323, rs17868324, rs11692021 SN-38 glucuronidation;
increased risk of toxicity; altered
response
[47,52,54]
UGT1A9 −118(dT) rs3832043 SN-30 glucuronidation; response [44,47,52,54]
XRCC1 Haplotype (−1149delGGCC, R399Q) rs321329 rs25487 Response [74]
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